MX2024009257A - Composiciones y metodos para inhibir la expresion de la proteina precalicreina (pkk). - Google Patents
Composiciones y metodos para inhibir la expresion de la proteina precalicreina (pkk).Info
- Publication number
- MX2024009257A MX2024009257A MX2024009257A MX2024009257A MX2024009257A MX 2024009257 A MX2024009257 A MX 2024009257A MX 2024009257 A MX2024009257 A MX 2024009257A MX 2024009257 A MX2024009257 A MX 2024009257A MX 2024009257 A MX2024009257 A MX 2024009257A
- Authority
- MX
- Mexico
- Prior art keywords
- pkk
- compositions
- methods
- prekallikrein
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21035—Tissue kallikrein (3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21008—Kallikrein (3.4.21.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21034—Plasma kallikrein (3.4.21.34)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022074535 | 2022-01-28 | ||
| PCT/CN2023/073501 WO2023143483A1 (en) | 2022-01-28 | 2023-01-28 | Compositions and methods for inhibiting expression of prekallikrein (pkk) protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009257A true MX2024009257A (es) | 2024-08-06 |
Family
ID=87470605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009257A MX2024009257A (es) | 2022-01-28 | 2023-01-28 | Composiciones y metodos para inhibir la expresion de la proteina precalicreina (pkk). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250145999A1 (https=) |
| EP (1) | EP4469570A1 (https=) |
| JP (1) | JP2025508324A (https=) |
| KR (1) | KR20240139057A (https=) |
| CN (1) | CN118510894A (https=) |
| AU (1) | AU2023210979A1 (https=) |
| CA (1) | CA3244243A1 (https=) |
| IL (1) | IL314396A (https=) |
| MX (1) | MX2024009257A (https=) |
| TW (1) | TW202346586A (https=) |
| WO (1) | WO2023143483A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12042509B2 (en) * | 2021-10-01 | 2024-07-23 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102365486B1 (ko) * | 2013-08-28 | 2022-02-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | 프리칼리크레인 (pkk) 발현의 조절 |
| HUE052709T2 (hu) * | 2014-05-01 | 2021-05-28 | Ionis Pharmaceuticals Inc | Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására |
| JP6695902B2 (ja) * | 2015-05-06 | 2020-05-20 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
| CN109762904A (zh) * | 2019-03-05 | 2019-05-17 | 中国医学科学院北京协和医院 | 与胰腺神经内分泌肿瘤相关的分子标记物及其应用 |
| US20220315929A1 (en) * | 2019-05-24 | 2022-10-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof |
| WO2021126734A1 (en) * | 2019-12-16 | 2021-06-24 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| BR112022015380A2 (pt) * | 2020-02-07 | 2022-09-27 | Intellia Therapeutics Inc | Composições e métodos para edição de gene de calicreína (klkb1) |
-
2023
- 2023-01-19 TW TW112102528A patent/TW202346586A/zh unknown
- 2023-01-28 MX MX2024009257A patent/MX2024009257A/es unknown
- 2023-01-28 EP EP23746361.7A patent/EP4469570A1/en active Pending
- 2023-01-28 AU AU2023210979A patent/AU2023210979A1/en active Pending
- 2023-01-28 CN CN202380015864.8A patent/CN118510894A/zh active Pending
- 2023-01-28 CA CA3244243A patent/CA3244243A1/en active Pending
- 2023-01-28 US US18/833,727 patent/US20250145999A1/en active Pending
- 2023-01-28 WO PCT/CN2023/073501 patent/WO2023143483A1/en not_active Ceased
- 2023-01-28 IL IL314396A patent/IL314396A/en unknown
- 2023-01-28 KR KR1020247025383A patent/KR20240139057A/ko active Pending
- 2023-01-28 JP JP2024543863A patent/JP2025508324A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202346586A (zh) | 2023-12-01 |
| CA3244243A1 (en) | 2023-08-03 |
| IL314396A (en) | 2024-09-01 |
| KR20240139057A (ko) | 2024-09-20 |
| CN118510894A (zh) | 2024-08-16 |
| US20250145999A1 (en) | 2025-05-08 |
| JP2025508324A (ja) | 2025-03-26 |
| EP4469570A1 (en) | 2024-12-04 |
| WO2023143483A1 (en) | 2023-08-03 |
| AU2023210979A1 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20250258A1 (ar) | مثبطات 2-آزا باي سيكلو هبتان kras | |
| MX2024003592A (es) | Composiciones y metodos para inhibir la expresion de la proteina de tipo angiopoyetina 3 (angptl3). | |
| MX2024014142A (es) | Novedosos inhibidores de molecula peque?a de factores de transcripcion tead | |
| BR112022024483A2 (pt) | Métodos para tratar mieloma múltiplo | |
| DOP2024000083A (es) | Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt) | |
| JOP20250098A1 (ar) | تركيبات تشتمل على إنزيمات قاطعة للأجسام المضادة وطريقة استخدامها | |
| MX2025010397A (es) | Compuestos heterociclicos como inhibidores de la helicasa del sindrome de werner (wrn) | |
| EA202091205A1 (ru) | Композиции для терапии гипергликемии и сопутствующих состояний | |
| MX2024009257A (es) | Composiciones y metodos para inhibir la expresion de la proteina precalicreina (pkk). | |
| MX2024014121A (es) | Metodos y composiciones para el tratamiento del exceso de glucocorticoides | |
| EA202193111A1 (ru) | Композиции и способы для лечения рака | |
| MX2025002705A (es) | Isoquinolonas como inhibidores de pi3k | |
| MX2025013771A (es) | Composiciones y metodos para inhibir la expresion del factor de coagulacion xi (fxi) | |
| MX2024015077A (es) | Benzopirimidina-4(3h)-onas como inhibidores de pi3k | |
| MX2024014450A (es) | Composiciones de genoterapia y metodos de uso de las mismas | |
| JOP20250276A1 (ar) | مثبطات masp-2 و masp-3 وتركيبات وطرق مرتبطة بها لمعالجة مرض الخلية المنجلية | |
| MX2025015672A (es) | Composiciones y metodos para inhibir la expresion del factor del complemento b (cfb) | |
| MX2023002416A (es) | Compuestos, composiciones y metodos para la inhibicion de la desmetilasa de histona lisina. | |
| MX2025014028A (es) | Arnbc de doble cadena dirigido a lpa y su uso | |
| Zhang et al. | Dipeptidyl peptidase-4 inhibition prevents lung injury in mice under chronic stress via the modulation of oxidative stress and inflammation | |
| JOP20240149A1 (ar) | مثبطات bcl-2 (الخلية ب لمفومة 2) | |
| MX2025015797A (es) | Composiciones y metodos para inhibir la expresion de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr) | |
| MX2026000754A (es) | Composiciones y metodos para inhibir la expresion del componente 3 del complemento (c3) | |
| PL437233A1 (pl) | Zastosowanie estrów cukrowych kwasów tłuszczowych, o komponencie kwasowej będącej mieszaniną monomerów uzyskanych z bakteryjnego polihydroksynonaniano -co- heptanianu, do hamowania proliferacji komórek nowotworowych w leczeniu i profilaktyce chorób | |
| MX2026001695A (es) | Agente de arni dirigido a rage y uso farmaceutico del mismo |